Episode 168: Aduhelm's latest twist, & how Covid variants are shaping the summer
First, we discuss the latest twists following the FDA's widely condemned decision to approve Aduhelm, Biogen's treatment for Alzheimer's disease. Then, our STAT colleague Helen Branswell joins us to t...
8 Heinä 202131min
Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga,
First we talk to George Yancopoulos, head scientist at Regeneron Pharmaceuticals, about the future of CRISPR genome editing and the latest idea for treating obesity. Then, we discuss STAT's reporting ...
1 Heinä 202143min
Episode 166: FDA inner workings, GSK's foggy future, & the alarming rise in colorectal cancer
First, we sift through the week's news, with a major update from Eli Lilly in Alzheimer's disease and new details on the inner workings of the FDA. Then, STAT's Matthew Herper joins us to discuss how ...
24 Kesä 202137min
Episode 165: Paul Offit on the Covid vaccine booster debate, & Robyn Karnauskas' call of the decade
First, we sift through the week's news, with some disappointing Covid-19 vaccine data, a pair of setbacks for biotech, and the Wall Street debut of 23andMe. Then, vaccinologist Paul Offit joins us to ...
17 Kesä 202134min
Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug
We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's suc...
10 Kesä 202140min
Episode 163: Marilynn Marchione on covering the CRISPR babies scandal
First, we discuss why it's so hard to predict FDA decisions, and why the latest big deal in biotech left investors cold. Then, STAT Washington correspondent Nicholas Florko joins us for a dive into th...
3 Kesä 202128min
Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA
STAT's Andrew Joseph joins us to talk about the two-year anniversary of the approval of gene therapy Zolgensma and the effect it has had on families dealing with the rare disease spinal muscular atrop...
27 Touko 202132min
Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity
First, we discuss Ginkgo Bioworks, the multibillion-dollar biotech company with grand ambitions, a famous ticker symbol, and an affinity for memes. Then, STAT’s Helen Branswell joins us to discuss a t...
20 Touko 202138min
